Get the Stockscreener App
598.62
0.16%
-1.1253
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $598.62, with a volume of 285.00K.
It is down -0.16% in the last 24 hours and up +2.31% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$599.75
Open:
$598
24h Volume:
285.00K
Relative Volume:
0.36
Market Cap:
$77.79B
Revenue:
$330.19B
Net Income/Loss:
$2.54B
P/E Ratio:
31.00
EPS:
19.31
Net Cash Flow:
$4.31B
1W Performance:
+0.68%
1M Performance:
+2.31%
6M Performance:
-3.03%
1Y Performance:
+15.82%
1-Day Range:
$591.13
$601.87
1-Week Range:
$570.51
$612.98
52-Week Range:
$464.42
$637.51
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
598.79 | 77.79B | 330.19B | 2.54B | 4.31B | 19.31 |
|
COR
Cencora Inc
|
247.86 | 47.73B | 293.96B | 1.51B | 3.00B | 7.51 |
|
CAH
Cardinal Health Inc
|
127.37 | 30.95B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
78.78 | 9.32B | 12.50B | 314.00M | 421.00M | 2.44 |
|
PDCO
Patterson Companies Inc
|
31.02 | 2.72B | 6.55B | 155.22M | -823.13M | 1.71 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
McKesson Corp. outlook revised to positive, 'BBB+' rating affirmed: S&P Global - Investing.com Australia
McKesson Third Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Value-Based Healthcare Market Projected To Witness Substantial Growth, 2025-2032: McKesson Corporation, - EIN News
Pharmaceuticals Wholesale & Distribution Market to grow by USD 896.5 Billion from 2024-2028, Driven by Growing Global Pharmaceutical Sales, Report on How AI is Driving Market Transformation - Benzinga
McKesson’s Earnings Call Highlights Strong Growth - TipRanks
McKesson, AmerisourceBergen's Joint Motion to Dismiss Antitrust Case Granted by Pennsylvania Judge - Marketscreener.com
McKesson to acquire majority stake in PRISM Vision for $850M - MSN
Decoding McKesson's Options Activity: What's the Big Picture? - Benzinga
Baird Adjusts Price Target on McKesson to $729 From $693 -February 06, 2025 at 11:28 am EST - Marketscreener.com
Leerink Partners Adjusts Price Target on McKesson to $690 From $667 -February 06, 2025 at 11:32 am EST - Marketscreener.com
McKesson to acquire controlling interest in Prism Vision - Drug Store News
Citi raises McKesson stock price target to $685 - Investing.com India
McKesson Corporation (NYSE:MCK) Q3 2025 Earnings Call Transcript - Insider Monkey
McKesson projects $32.55-$32.95 adjusted EPS for FY25, driven by specialty growth - MSN
McKesson's Q4 Revenue Grows by 17.8% but Falls Short of ExpectationsNews and Statistics - IndexBox, Inc.
MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts - Yahoo Finance
McKesson Corp Reports Q3 Revenue of $95.3 Billion, Adjusted EPS of $8.03 Surpasses Estimates - GuruFocus.com
McKesson Corp (MCK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions - GuruFocus.com
McKesson Corp (MCK) Q3 2025 Earnings Call Highlights: Strong Rev - GuruFocus.com
McKesson Corp (MCK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
McKesson Reports Strong Growth and Raises EPS Guidance - TipRanks
McKesson (MCK) Q3 2025 Earnings Call Transcript - AOL
McKesson: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
McKesson Stumbles On Missed Revenue Target Despite High Demand - Finimize
McKesson misses third-quarter revenue estimates - MSN
McKesson misses third-quarter revenue estimates By Reuters - Investing.com
Here's What Key Metrics Tell Us About McKesson (MCK) Q3 Earnings - Yahoo Finance
McKesson Exceeds EPS, Q3 Profit Surges - The Motley Fool
McKesson falls 3% on quarterly revenue miss, narrowed fiscal 2025 EPS outlook - MSN
McKesson (NYSE:MCK) Misses Q4 Sales Targets - Yahoo Finance
McKesson: Fiscal Q3 Earnings Snapshot -February 05, 2025 at 04:33 pm EST - Marketscreener.com
McKesson shares fall as Q3 results miss estimates, guidance raised By Investing.com - Investing.com Australia
McKesson Fiscal Q3 Adjusted EPS, Revenue Increase; 2025 Outlook Updated -- Shares Down After Hours - Marketscreener.com
McKesson shares fall as Q3 results miss estimates, guidance raised - Investing.com
McKesson Q3 Earnings Report: What Investors Need to Know - Benzinga
McKesson earnings missed by $0.24, revenue fell short of estimates - Investing.com
McKesson Reports Q3 EPS of $8.03 on Revenue of $95.3 Billion, vs FactSet Analyst Consensus of $8.00/Share on Revenue of $96 Billion - Marketscreener.com
McKesson Narrows FY 2025 EPS View to $32.55-$32.95, vs Prior Guidance of $32.40-$33 and FactSet Analyst Consensus of $32.68/Share - Marketscreener.com
McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance - The Bakersfield Californian
McKesson Q3 Earnings Surpass Expectations, Boosts 2025 Profit Outlook - StockTitan
McKesson Q3 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
McKesson Stock May Rise With PRISM Vision Holdings Acquisition - Yahoo Finance Australia
McKesson, Others Beat Indirect Drug Reseller Price-Fix Suit - Law360
McKesson Paying $850M For Top Stake In Eye Health Co. - Law360
Eyeing Ophthalmology in $850M Deal, Irving's McKesson To Snag Controlling Interest in PRISM Vision Holdings - dallasinnovates.com
MCKMcKesson Corporation Latest Stock News & Market Updates - StockTitan
McKesson to acquire majority stake in PRISM Vision for $850M By Investing.com - Investing.com South Africa
McKesson to buy controlling stake in eye services organization for $850M - The Business Journals
McKesson to Acquire 80% Stake in PRISM Vision Holdings for $850 Million - GuruFocus.com
McKesson Co. (NYSE:MCK) Holdings Raised by E. Ohman J or Asset Management AB - MarketBeat
Deutsche Bank Adjusts Price Target on McKesson to $628 From $622 -February 04, 2025 at 09:23 am EST - Marketscreener.com
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):